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A 64-year-old female presented to the emergency room with
persistent dizziness that began early that morning. She had a
30-year history of palpitations and known electrocardiogram
(ECG) abnormalities. Her pulse was irregular at 130–270 min1
and blood pressure was 90/40 mmHg. There were no other
abnormalities on physical examination. A chest X-ray was normal
and without cardiomegaly. Echocardiography revealed normal
left ventricular contraction without structural abnormalities.
Blood chemistry evaluation, including electrolytes and cardiac
enzymes, was within normal limits. Twelve-lead ECG showed
irregular wide QRS tachycardia of various conﬁgurations (Fig. 1).
How would you diagnose her tachycardia?2. Commentary
The patient’s ECG shows wide QRS tachycardia with a rate from
150 to 300 beats/min. The RR intervals are irregularly irregular and
no P wave preceding QRS was conﬁrmed. The QRS complex has
beat–beat variations in morphology. At this point, some of the
arrhythmias that should be considered are: (1) irregular ventricular
tachycardia (such as torsades des pointes or polymorphic ventricular
tachycardia); (2) atrial ﬁbrillation (AF) with bundle branch block; (3)
AF in Wolff–Parkinson–White (WPW) syndrome (pseudo-ventricu-
lar tachycardia). The QRS complex shows right axis deviation during
tachycardia with no progressive change in cardiac axis, thus poly-
morphic ventricular tachycardia and torsades des pointes associated
with QT prolongation are excluded. Polymorphic ventricular tachy-
cardia associated electrolyte abnormality and myocardial ischemia
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The representative arrhythmia of the patient’s irregular heart
rate is AF, which is the most common cardiac arrhythmia. When
the ventricular rate is slow, AF can be easily diagnosed. However
if the ventricular rate is rapid, AF is difﬁcult to appreciate because
QRS complexes are clustered together and ﬁbrillatory waves
become more difﬁcult to evaluate. The QRS complexes during
AF with bundle branch block usually do not have beat–beat
variation, and both an Rr0 pattern in lead V1 and RoS amplitude
in V6 are uncommon for the ECG of right bundle branch block. On
the other hand, the QRS complexes during AF in WPW syndrome
are extremely bizarre and broad because the QRS complex reﬂects
varying degrees of fusion of ventricular activation via the atrio-
ventricular (AV) node and accessory pathways.
To terminate AF and block the accessory pathway, procainamide
was given intravenously at a dose of 400 mg over 30 min. It is
important to note that AV nodal blocking agents are contraindi-
cated in treatment of AF in patients withWPW syndrome. AV nodal
blocking agents, for example verapamil and digoxin, decrease the
number of impulses conducted through the His–Purkinje system
and enhance conduction across accessory pathways, thus increasing
the ventricular rate during AF. If the patient is hemodynamically
unstable, electrical cardioversion should be performed. After infu-
sion of procainamide, this patient’s AF converted to normal sinus
rhythm (Fig. 2) that included a short PR interval and a delta wave.
A positive delta wave and QRS in V1 indicated a left sided accessory
pathway.3. Explanations of the arrhythmia
AF is the most serious arrhythmia associated with WPW
syndrome. This arrhythmia has the possibility of degenerating
into ventricular ﬁbrillation, which can cause sudden cardiac
death. Although the occurrence of ventricular ﬁbrillation is rare,
even among symptomatic patients with WPW syndrome, AF
carries the potential for sudden cardiac death. The risk of suddenlsevier B.V. All rights reserved.
Fig. 1. Twelve-lead ECG during tachycardia in the emergency room.
Fig. 2. Twelve-lead ECG during sinus rhythm after infusion of procainamide.
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short effective refractory period of the anterograde accessory
pathway. Electrophysiological studies are performed to measure
the refractory period of the accessory pathway. Patients with an
accessory pathway with an effective refractory period of less than
250 ms, as measured by an R–R interval between 2 preexcited
complexes of o250 ms during AF, are deﬁned as high risk.
This patient’s shortest R–R interval on ECG was about 200 ms
(300 bpm), which indicated high risk of sudden cardiac death. The
patient underwent catheter ablation. ACC/AHA/ESC guidelines for
the management of patients with supraventricular arrhythmias
[1], which include accessory pathway-mediated arrhythmias,
recommend catheter ablation for long-term therapy in patients
with symptomatic WPW syndrome (Class I).
The classic preexcitation syndrome was described by Wolff,
Parkinson, and White in 1930 as an ECG demonstrating bundle
branch block with short P–R interval. With advances in clinical
electrophysiological study, this syndrome is currently proposed to
be due to preexcitation of the ventricle by an accessory path-
way(s). The prevalence of WPW syndrome has been estimated to
be 0.1–0.3% in the general population [2]. The most important
clinical consequence of WPW syndrome is supraventricular
tachycardia consisting of AV reciprocating tachycardia (AVRT).
During orthodromic AVRT, the impulse is conducted from
atrium to ventricle across the AV node, resulting in narrow QRS
complex. Conversely, during antidromic AVRT, the impulse is
conducted from atrium to ventricle across the accessory pathway,
resulting in wide QRS complexes. Occasionally, patients with
AVRT develop AF that may lead to hemodynamic deterioration
owing to anterograde conduction over the accessory pathway.
The incidence of AF in patients with WPW syndrome is
reported to be 10–30% [3–5]. No relationship between the onset
of AF and localization of accessory pathways has been reported
[6], and successful ablation of the accessory pathway prevents the
recurrence of AF in the majority of patients. It is known that an
accessory pathway is associated with AF, but this mechanism has
not been clariﬁed. Recently, a potential role of the pulmonaryveins in the development of AF in patients with WPW syndrome
was reported [7].
In Japan and some European countries, AF in WPW syndrome
is generally referred as pseudo-ventricular tachycardia. However,
this term is rarely used in the United States because it may lead
physicians to misinterpret the mechanism of the arrhythmia.Conﬂict of interest
None.
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